ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,753.70
0.35%
S&P ASX All Technology
3,050.50
0.56%
Brent Oil
82.60
0.06%
US Dollar vs AUD
1.49506
-0.97%
Bitcoin
65,442.39
6.32%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NGM Biopharmaceuticals Inc (NGM)

  7. NGM Biopharmaceuticals Inc (NGM) News

NGM

NGM Biopharmaceuticals (NGM)

NGM Biopharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NGM
DateTimeSourceHeadlineSymbolCompany
06/04/202400:19GlobeNewswire Inc.NGM Bio Announces Closing of Tender OfferNASDAQ:NGMNGM Biopharmaceuticals Inc
20/03/202408:30GlobeNewswire Inc.NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual MeetingNASDAQ:NGMNGM Biopharmaceuticals Inc
12/03/202407:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NGMNGM Biopharmaceuticals Inc
12/03/202407:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
12/03/202407:05GlobeNewswire Inc.NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:NGMNGM Biopharmaceuticals Inc
09/03/202409:32Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:NGMNGM Biopharmaceuticals Inc
09/03/202409:21Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:NGMNGM Biopharmaceuticals Inc
27/02/202409:11Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:NGMNGM Biopharmaceuticals Inc
27/02/202409:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
27/02/202401:03GlobeNewswire Inc.NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPNASDAQ:NGMNGM Biopharmaceuticals Inc
21/02/202408:01GlobeNewswire Inc.NGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceNASDAQ:NGMNGM Biopharmaceuticals Inc
15/02/202410:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NGMNGM Biopharmaceuticals Inc
22/01/202422:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
19/01/202410:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
19/01/202410:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
19/01/202410:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
18/01/202408:47GlobeNewswire Inc.NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:NGMNGM Biopharmaceuticals Inc
10/01/202400:00GlobeNewswire Inc.NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet NeedNASDAQ:NGMNGM Biopharmaceuticals Inc
02/01/202423:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
05/12/202309:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
05/12/202308:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
14/11/202301:45GlobeNewswire Inc.NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®NASDAQ:NGMNGM Biopharmaceuticals Inc
09/11/202310:13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
09/11/202310:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
09/11/202310:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
09/11/202310:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
08/11/202308:05GlobeNewswire Inc.NGM Bio to Participate in Upcoming Investor ConferencesNASDAQ:NGMNGM Biopharmaceuticals Inc
03/11/202307:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NGMNGM Biopharmaceuticals Inc
03/11/202307:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
03/11/202307:01GlobeNewswire Inc.NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:NGMNGM Biopharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:NGM

Your Recent History

LSE
0QW3
Interma Trade
LSE
0Q34
TSX
BXF
CI 1 5 Year Laddered Gov...
USOTC
APPEF
Appen (PK)
AMEX
AGGE
IQ Enhanced Core Bond US...
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved